Phase 3 program reporting results
NDA 215256 · FDA-approved prescription drug
Peptide comparison workspaceCompare status.
Compare status.
Follow the evidence.
Compare any two published peptide or GLP-1 records across evidence status, clinical trials, 42 country verification routes, and qualified US research prices. Each lens stays attached to the source category that can support it.
Search the complete peptide database Download the open evidence index Open the complete 20-board matrix40selectable peptide and medicine records
211linked evidence records
42country verification routes per record
20qualified research price boards
Universal peptide comparison
Compare FDA status, trial coverage, aliases, and evidence.
Choose any two published records. The comparison keeps approved medicines, clinical programs, and research-market listings in their correct categories, including blank-versus-zero rules for the bounded clinical-trial snapshot.
FDA-approved medicine7
Investigational clinical program13
US research price board20
Record count shows published coverage, not evidence quality, safety, or clinical strength.
North AmericaUnited States · July 18, 2026Country selection changes the verification route, not the underlying compound identity.
Retatrutide vs WEGOVY (Semaglutide)
These records belong to different evidence categories. Retatrutide is tracked as an investigational clinical program, while WEGOVY (Semaglutide) is tracked as an FDA-approved medicine. The table helps resolve identity and status. It does not make the products clinically or commercially equivalent. The country lens is set to United States.
2 recruiting · 2 with posted results
Blank means outside this 13-program dataset, not zero trials.
Local status requires the destination records.
Open exact United States guide →1 country-specific source record is attached.
Open exact United States guide →Blank preserves the evidence category. It is not a zero price or a missing medicine cost estimate.
Open qualified matrix →Blank preserves the evidence category. It is not a zero price or a missing medicine cost estimate.
Open qualified matrix →FieldRetatrutideWEGOVY (Semaglutide)
Evidence category
Investigational clinical program
FDA-approved medicine
Question answered
Sponsor, phase, trial record, mechanism, and reported findings
Exact product approval, label, route, and regulatory record
Aliases and codes
LY3437943, triple agonist, reta, reta peptide
semaglutide, Wegovy, NDA 215256, GLP-1 receptor agonist, semaglutide injection, semaglutide tablets, oral Wegovy, Wegovy pill, sémaglutide, semaglutida, Semaglutid, 司美格鲁肽
Family
Obesity and metabolic pipeline
FDA-approved incretin medicine
Sponsor, company, or board
Eli Lilly and Company
Novo Nordisk Inc.
Current record
Phase 3 program reporting results
NDA 215256 · FDA-approved prescription drug
Route or listing detail
GIP + GLP-1 + glucagon receptor agonist · Once-weekly subcutaneous injection
Injection and tablets · Subcutaneous and oral
Published evidence coverage
4 linked records
7 linked records
Last checked
July 20, 2026
July 18, 2026
ClinicalTrials.gov snapshot
34 matched NCT records2 recruiting · 2 results postedOpen filtered trial finder →
Not indexed by the current 13-program snapshotBlank is a scope boundary, not evidence that no trial history exists.Open the bounded trial finder →
How to read a peptide comparison
Start with status, then compare the fields that actually match.
Which peptides are FDA approved?
An approved medicine record names the exact active ingredient, brand, application, labeled use, route, and company. A similar peptide name on a research seller page does not inherit that approval.
Browse FDA-approved medicine records →What does investigational mean?
An investigational program is being studied but is not an approved retail product. Compare sponsor, phase, registry records, population, duration, and outcome definitions before interpreting a headline result.
Browse the clinical pipeline →How does country status change a comparison?
A sponsor record, FDA approval, or US research listing is only the starting identity. The destination country’s product record and its separate seller or supply register decide what can be supported locally.
Open the 42-country source router →Can research peptide prices be compared?
Yes, when nominal vial size, visible list price, seller market, availability, and checked date match. Those commercial fields still do not establish clinical equivalence or laboratory quality.
Open the complete price matrix →Research-market price comparison
Compare exact-size US price boards.
This second tool covers 20 research-market boards and 190 possible pairs. It normalizes visible commercial fields only. It does not compare clinical effects, doses, or treatment suitability.
Read the price comparison methodInteractive comparison
Choose any two price boards.
Every option is a qualified, exact-size US research board. The tool compares commercial and evidence fields only; it does not compare effects, doses, or treatment suitability.
CJC-1295 no DAC vs CJC-1295 DAC
Research-market snapshot checked Jul 23, 2026. Dollar-per-milligram normalization corrects the unit only; it does not imply equivalent identity or research value.
CJC-1295 no DAC
Modified growth hormone-releasing factor analogue research material
- Board
- 5 mg
- From
- $46.00
- Rows
- 3
CJC-1295 DAC
Drug-affinity-complex growth hormone-releasing factor analogue research material
- Board
- 5 mg
- From
- $46.00
- Rows
- 3
| Comparison field | CJC-1295 no DAC | CJC-1295 DAC |
|---|---|---|
| Editorial family | Growth-signaling analogues | Growth-signaling analogues |
| Seller-listed identity | Modified growth hormone-releasing factor analogue research material | Drug-affinity-complex growth hormone-releasing factor analogue research material |
| Nominal board size | 5 mg | 5 mg |
| Available list range | $46.00–$74.79 | $46.00–$52.00 |
| Median available price | $60.40 | $49.00 |
| Lowest available / mg | $9.20 | $9.20 |
| Available rows | 2 of 3 | 2 of 3 |
| Public evidence routes | 2 rows | 3 rows |
| Evidence only on request | 1 rows | 0 rows |
| Available-price spread | 63% | 13% |
| Snapshot checked | Jul 23, 2026 | Jul 23, 2026 |
Quality-gated pair guides
The comparisons that need more than a table.
Only pairs with a defensible identity or commercial comparison need, substantial pair-specific context, shared family, and current seller coverage receive dedicated pages. Every other pair remains available in the interactive tools above.
BPC-157
vs TB-500
Both sit in Peptide Local’s tissue and thymic research family and share much of the same seller set, so readers often need to separate a genuine price-footprint comparison from an unsupported equivalence claim.
- Board sizes
- 10 / 10 mg
- Shared sellers
- 7
CJC-1295 no DAC
vs CJC-1295 DAC
This is the site’s clearest same-name collision: seller pages may shorten either format to CJC-1295, making exact label, nominal size, and source URL essential before prices are compared.
- Board sizes
- 5 / 5 mg
- Shared sellers
- 2
Selank
vs Semax
Both belong to the neuropeptide family in the research index and are frequently stocked by the same specialist sellers, creating a useful commercial comparison but a high risk of over-reading seller descriptions.
- Board sizes
- 10 / 10 mg
- Shared sellers
- 2
Melanotan I
vs Melanotan II
The two names share a melanocortin family and nearly identical shorthand, so exact-domain seller pages and explicit I-versus-II labels are necessary to prevent price or evidence from being assigned to the wrong material.
- Board sizes
- 10 / 10 mg
- Shared sellers
- 3
Tesamorelin
vs Sermorelin
Searchers often group the two by growth-signaling terminology, but the different catalog identities and nominal board sizes make this an important test of whether a comparison keeps units and category claims honest.
- Board sizes
- 10 / 5 mg
- Shared sellers
- 3
Ipamorelin
vs CJC-1295 no DAC
The pair is commonly cross-shopped in online research catalogs, making it useful to compare commercial coverage while explicitly refusing the stack, protocol, dosage, or outcome claims that often accompany the search.
- Board sizes
- 10 / 5 mg
- Shared sellers
- 1
PT-141 (Bremelanotide)
vs Melanotan II
The search is an identity trap because PT-141 connects by ingredient name to an approved medicine record while Melanotan II remains a separate research-market entity. A useful comparison must preserve all three lanes.
- Board sizes
- 10 / 10 mg
- Shared sellers
- 2
Interpretation rule
Comparable fields do not create equivalent compounds.
A board can normalize dollars, milligrams, public evidence access, and availability. It cannot normalize molecular identity, potency, research purpose, clinical evidence, safety, or personal suitability.
Open the evidence-status map